Skip to main content
Journal cover image

Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus.

Publication ,  Journal Article
Barbery, CE; Giczewska, A; White, J; Lokhnygina, Y; Mentz, RJ; Holman, RR; Pagidipati, N; Hernandez, AF; Jones, WS
Published in: Am Heart J
September 2021

Cardiovascular (CV) outcome studies of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shifted the paradigm of type 2 diabetes management given their benefits regarding a reduction in major adverse CV events. However, the relationship between GLP-1 RAs and coronary revascularization remains poorly understood. In this EXSCEL post-hoc analysis, we used univariate Cox proportional models and Kaplan Meier survival analysis to evaluate the effect of once-weekly exenatide (EQW) on a composite outcome of hospitalization for acute coronary syndrome (ACS) or coronary revascularization. Similar models were utilized to evaluate the relationship between significant participant characteristics within the entire study population and the composite outcome. Of the 14,736 participants in EXSCEL with complete follow-up data, 1642 (11.1%) experienced an ACS or coronary revascularization event during a median follow-up of 3.3 years (interquartile range, 2.3-4.4). EQW had no effect on hospitalization for ACS or coronary revascularization (HR 1.00, 95% CI 0.91-1.10). Among EXSCEL participants, enrollment in Latin America (HR 0.51, 95% CI 0.43-0.60) and a history of peripheral artery disease (HR 0.79, 95% CI 0.70-0.90) were associated with a reduced risk for coronary revascularization, whereas enrollment in North America (HR 1.92, 95% CI 1.74-2.12), a history of CV disease (HR 3.24, 95% CI 2.78-3.78), and a previous myocardial infarction (HR 1.54, 95% CI 1.39-1.71) were associated with increased risk for study end points. EQW had no association with hospitalization for ACS or coronary revascularization. Participant enrollment location and CV disease burden may play a role in the variable CV efficacy of GLP-1 RAs that has been observed in trials thus far.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

September 2021

Volume

239

Start / End Page

59 / 63

Location

United States

Related Subject Headings

  • Proportional Hazards Models
  • Outcome and Process Assessment, Health Care
  • Myocardial Revascularization
  • Middle Aged
  • Male
  • Kaplan-Meier Estimate
  • Hypoglycemic Agents
  • Humans
  • Hospitalization
  • Glucagon-Like Peptide-1 Receptor
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Barbery, C. E., Giczewska, A., White, J., Lokhnygina, Y., Mentz, R. J., Holman, R. R., … Jones, W. S. (2021). Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus. Am Heart J, 239, 59–63. https://doi.org/10.1016/j.ahj.2021.03.013
Barbery, Carlos E., Anna Giczewska, Jennifer White, Yuliya Lokhnygina, Robert John Mentz, Rury R. Holman, Neha Pagidipati, Adrian F. Hernandez, and W Schuyler Jones. “Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus.Am Heart J 239 (September 2021): 59–63. https://doi.org/10.1016/j.ahj.2021.03.013.
Barbery CE, Giczewska A, White J, Lokhnygina Y, Mentz RJ, Holman RR, et al. Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus. Am Heart J. 2021 Sep;239:59–63.
Barbery, Carlos E., et al. “Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus.Am Heart J, vol. 239, Sept. 2021, pp. 59–63. Pubmed, doi:10.1016/j.ahj.2021.03.013.
Barbery CE, Giczewska A, White J, Lokhnygina Y, Mentz RJ, Holman RR, Pagidipati N, Hernandez AF, Jones WS. Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus. Am Heart J. 2021 Sep;239:59–63.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

September 2021

Volume

239

Start / End Page

59 / 63

Location

United States

Related Subject Headings

  • Proportional Hazards Models
  • Outcome and Process Assessment, Health Care
  • Myocardial Revascularization
  • Middle Aged
  • Male
  • Kaplan-Meier Estimate
  • Hypoglycemic Agents
  • Humans
  • Hospitalization
  • Glucagon-Like Peptide-1 Receptor